PACE BOM chemotherapy: A 12-week regimen for advanced Hodgkin's disease

Annals of Oncology

Volumn 8, Issue 3, 1997, Pages 259-266

  Simmonds, P D ^a   Mead, G M ^a   Sweetenham, J W ^a   O'Callaghan, A ^a   Smartt, P ^a   Kerr, J ^a   Hamilton, C R ^a   Golding, P F ^b   Milne, A E ^c   Whitehouse, J M A ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

chemotherapy; Hodkin's disease; phase II study; radiotherapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL; THROMBOCYTOPENIA; VOMITING;

EID: 8244263611     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008282020341     Document Type: Article

References (42)

1. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-1306.
2. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
3. Bonadonna G, Valagussa P, Santoro A. Alternating non cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 1986; 104: 739-46.
4. Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-72.
5. Santoro A, Bonadonna G, Valagussa P et al. Long term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
6. Tucker MA, Coleman CN, Cox RS et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76-81.
7. Waxman JHX, Terry YA, Wrigley PFM et al. Gonadal function in Hodgkin's disease: long term follow up of chemotherapy. BMJ 1982; 285: 1612-3.
8. Schilsky RL, Sherins RJ. Hubbard SM et al. Long term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71: 552-6.
9. Selby P, Patel P, Milan S et al. ChIVPP combination chemotherapy for Hodgkin's disease: long term results. Br J Cancer 1990; 62: 279-85.
10. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten year results. J Clin Oncol 1996; 14: 1421-30.
11. Viviani S, Santoro A, Ragni G et al. Gonadal toxicty after combination chemotherapy for Hodgkin's disease: comparitive results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601-5.
12. Foss Abrahamson J, Andersen A, Hannisdal et al. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow up time and age. J Clin Oncol 1993; 11: 255-61.
13. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13.
14. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-55.
15. Lund MB, Kongerud J, Nome O et al. Lung function impairment in long term survivors of Hodgkin's disease. Ann Oncol 1995; 6: 495-501.
16. Valagussa P, Santoro A, Fossati-Bellani et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830-7.
17. Sweetenham JW, Mead GM, Whitehouse JMA. Intensive weekly chemotherapy for patients with intermediate grade and high grade non-Hodgkin's lymphoma. J Clin Oncol 1991; 9: 2202-9.
18. Bartlett NL, Rosenberg SA, Hoppe RT et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080-8.
19. Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
21. Kaplan EL, Meier P. Non parametric estmation of incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
22. Cosset JM, Henry-Amar M, Meerwaldt JH. Long term toxicity of early stages of Hodgkin's disease: the EORTC experience. Ann Oncol 1991; 2: 77-82.
23. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
24. Sorensen K, Levitt G, Sebag-Montefiore D et al. Cardiac function in Wilm's tumour survivors. J Clin Oncol 1995; 13: 1546-56.
25. Fryer CJ, Hutchinson RJ, Krailo M et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low dose regional radiation in advanced Hodgkin's disease in children: A report from the children's cancer study group. J Clin Oncol 1990; 8: 1971-80.
26. Horning SJ, Adhikari A, Rizk N et al. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol 1994; 12: 297-305.
27. Schmoll H. Review of etoposide single agent activity. Cancer Treat Rev 1982; 9 (Suppl A): 21-30.
28. O'Dwyer PJ, Leyland-Jones B, Alonso MT et al. Etoposide (VP-16-213): current status of an active anticancer drug. N Engl J Med 1985; 312: 692-700.
29. Pui CH, Riberio RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophylotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-7.
30. Winick NJ, Mckenna RW, Shuster JJ et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993; 11: 209-17.
31. Horning SJ, Hoppe RT, Hancock SL et al. Vinblastine, Bleomycin and Methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6: 1822-31.
32. Bates NP, Williams MV, Bessell EM et al. Efficacy and toxicity of Vinblastine. Bleomycin, and Methotrexate with involved feild radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 1994; 12: 288-96.
33. Yahalom J, Ryu J, Strauss DJ et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9: 2193-2201.
34. Brizel DM, Winer EP, Prosnitz LR et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990; 19: 535-42.
35. Fabian CJ, Mansfeild CM, Dahlberg S et al. Low dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120: 903-12.
36. Diehl V, Loeffler M, Pfreundschuh M et al. Further chemotherapy versus low dose involved field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol 1995; 6: 901-10.
37. Longo DL, Russo A, Duffey PL et al. Treatment of advanced stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol 1991; 9: 227-35.
38. Behar RA, Horning SJ, Hoppe RT. Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy. Int J Radiat Biol Phys 1993; 25: 771-6.
39. Leopold KA, Canellos GP, Rosenthal D et al. Stage IA-IIB Hodgkin's disease: Staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 1989; 7: 1059-65.
40. Diehl V, Pfreundschuh M, Loffler M et al. Combined modality therapy for stages I-IIIA massive mediastinal Hodgkin's disease (MMHD): A randomized trial of two cycles of COPP+ABVD plus extended field (EF) radiotherapy 40 Gy versus 20 Gy (bulky disease 40 Gy). Proc Am Soc Clin Oncol 1989; 8: 253 (Abstr 988).
41. Hoppe RT, Coleman CN, Cox RS et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 1982; 59: 455-65.
42. Hill M, Milan S, Cunningham D et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995; 13: 387-95.